UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin

January 6, 2018

(Length of presentation: 17 min)

Alicia Morgans, MD discusses the UPWARD Study with Susan Slovin, MD, PhD.  A study Dr. Slovin was a part of conducting to answer the question “Are seizure rates affected by treatment with enzalutamide in patients with metastatic castration-resistant prostate cancer who have seizure risk factors?”  Dr. Slovin discusses with Dr. Morgans the reasons for conducting the UPWARD study and the importance of understanding all the medications that patients are taking and their adverse effects.

In this open-label safety study of 423 patients receiving enzalutamide for metastatic castration-resistant prostate cancer, 4 patients experienced a confirmed seizure within the 4-month study period and 3 patients experienced a confirmed seizure following the 4-month study period. This incidence is similar to that in patients with metastatic castration-resistant prostate cancer and similar seizure risk factors but no enzalutamide exposure.


Susan Slovin, MD, PhD, is Attending Physician and Member in the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine, Department of Medicine at Joan and Sanford I Weill Medical College of Cornell University.  A noted immunologist, she has been involving with the Prostate Cancer Foundation in leading an initiative which focuses on the development of novel immunologic approaches for the treatment of prostate cancer. She is a member of several professional associations, including the American Society of Clinical Oncology, American Association of Immunologists, American Association of Investigative Pathology, and American Association of Cancer Researchers, American Urologic Association and Sigma Xi Research Society. 

Alicia Morgans, MD, MPH

Related Content

The UPWARD Study: Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure

mCRPC Treatment: The Right Treatment for the Right Patient at the Right Time: EVERYDAY UROLOGY- Full Text Article